COVID-19 in South Asian communities

Professor John Chambers

LKC School of Medicine, Singapore Imperial College London, UK






Non-communicable disease in South Asian populations

Group Aims

Aetiology: What are the behavioural, environmental and molecular factors that drive chronic disease in Asian populations?

Translation: How can we deliver 'Personal' and 'Population' based approaches for health promotion in Asian settings?

T2D incidence: South Asians vs Europeans



Model	RR (95%CI) of T2D in South Asians vs Europeans	P=	
Age , sex	2.62 (2.33 to 2.96)	6.1E-56	
+ BMI, WHR	2.66 (2.34 to 3.01)	4.6E-53	
+ Glycaemic traits	2.23 (1.93 to 2.58)	6.6E-28	
+ Physical activity	2.19 (1.90 to 2.57)	2.4E-26	
+ Amino acids	2.21 (1.90 to 2.57)	8.4E-25	
+ Genetic risk score	2.11 (1.80 to 2.47)	9.9E-21	

Global Health Research Unit Surveillance study


150,000 South Asians with rich phenotypes and samples













COVID-19 and study activity

Study recruitment





Phase 1


June 2020


28,909 participants re-interviewed

1% reported symptoms suggestive of COVID-19










Impact of COVID-19 in South Asians



UK Biobank: South Asians are at increased risk of COVID-19




Fig. 1 Risk ratios for associations between broad ethnicity groups (white British as the reference category) and SARS-CoV-2. Model 1: age, sex and assessment centre. Model 2: model 1 + country of birth. Model 3: model 2 + healthcare worker. Model 4: model 3 + social variables (urbanicity, number of people per household, highest education level, deprivation, tenure status, employment status, manual work). Model 5: model 4 + health status variables (self-rated health, number of chronic conditions and longstanding illness) + behavioural risk factors (smoking, alcohol consumption and BMI). Coefficients for the Chinese and other groups are not shown

Article

Factors associated with COVID-19-related death using OpenSAFELY

https://doi.org/10.1038/s41586-020-2521-4 Received: 15 May 2020 Accepted: 1 July 2020 Published online: 8 July 2020 Check for updates

Elizabeth J. Williamson^{1,6}, Alex J. Walker^{2,6}, Krishnan Bhaskaran^{1,6}, Seb Bacon^{2,6}, Chris Bates^{3,6}. Caroline E. Morton², Helen J. Curtis², Amir Mehrkar², David Evans², Peter Inglesby², Jonathan Cockburn³, Helen I. McDonald^{1,4}, Brian MacKenna², Laurie Tomlinson¹, Ian J. Douglas¹, Christopher T. Rentsch¹, Rohini Mathur¹, Angel Y. S. Wong¹, Richard Grieve¹, David Harrison⁵, Harriet Forbes¹, Anna Schultze¹, Richard Croker², John Parry³, Frank Hester³, Sam Harper³, Rafael Perera², Stephen J. W. Evans¹, Liam Smeeth^{1,4,7} & Ben Goldacre^{2,7 \to 3}

COVID-19 mortality amongst >23M people using UK electronic medical records

	Age/sex adjusted	'Fully adjusted'
White	1.00 (ref)	1.00 (ref)
Mixed	1.62 (1.26–2.08)	1.43 (1.11–1.84)
South Asian	1.69 (1.54–1.84)	1.45 (1.32–1.58)
Black	1.88 (1.65–2.14)	1.48 (1.29–1.69)
Other	1.37 (1.13–1.65)	1.33 (1.10–1.61)
	/ ^	

Potential limitations

- UK Biobank: 7,323 South Asians
- OpenSAFELY:
 - No biological samples
 - Incomplete baseline data
- Limited data for South Asia

Phase 2

Aims

- Determine the incidence of COVID-19 and its major complications in South Asian populations from India and the UK.
- Identify the primary risk factors predicting adverse COVID-19 outcomes in South Asians.
- Investigate whether known / novel risk factors account for differences in COVID-19 outcomes between South Asians and Europeans

Outcome variables

Primary COVID-19 endpoints:

- Total: all with confirmed SARS-CoV2 infection
- ii. Severe: COVID-19 (hospital admission or main / contributory cause for death)
- iii. Prolonged: persistent symptoms after 6 weeks.

Outcomes identification


- WS1: Clinical follow-up
 - Evaluate 30,000 South Asians for COVID-19
 - Three existing cohorts:
 - **LOLIPOP study** (UK; N=19,000)
 - iHealth-T2D (UK and South Asia; N=24,000)
 - GHRU Surveillance study (South Asia, N=53,000)
 - Questionnaire: WT/IHCC template
 - Blood sample: COVID-19 serology (Roche N&S?)
- WS2: Record linkage
 - UK: NHS and mortality data
 - India: ICMR COVID-19 registry

Analysis

- WS3: Molecular phenotyping
 - Collate existing molecular data
 - New GWAS on 2,500 COVID cases / controls

- WS4: Analysis
 - Incidence in UK and SA communities
 - Risk factors for COVID-19 outcomes:
 Environmental, behavioural & molecular factors.
 - Primary determinants of the 'excess risk' in SA

Timelines



Funding





The collaboration

Imperial College London



NIHR Global Health Research Unit

on Diabetes and Cardiovascular Disease in South Asia

